AngioDynamics Inc. has announced the publication of the results from the PRESERVE study in European Urology, focusing on the NanoKnife® System for prostate tissue ablation in patients with intermediate-risk prostate cancer. The peer-reviewed study assessed the safety and effectiveness of irreversible electroporation and demonstrated high disease control and quality-of-life preservation, supporting its use as a focal therapy. The study's primary effectiveness endpoint was met, with 84.0% of participants free from in-field, clinically significant disease at 12 months post-procedure. Additionally, the study reported strong preservation of urinary continence and sexual function. These findings are part of a broader body of evidence from over 32 clinical studies involving more than 2,600 patients worldwide.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.